Watabe T, Iwasawa T, Kimura H, Shirakami Y, Naka S, Kaneda K
Eur J Nucl Med Mol Imaging. 2025; .
PMID: 39934299
DOI: 10.1007/s00259-025-07139-9.
Zhang Y, Shi R, Meng R, Lin S, Zheng M
World J Gastrointest Oncol. 2024; 16(9):3781-3797.
PMID: 39350985
PMC: 11438782.
DOI: 10.4251/wjgo.v16.i9.3781.
Giordano G, Tucciarello C, Merlini A, Cutrupi S, Pignochino Y
Cell Commun Signal. 2024; 22(1):433.
PMID: 39252029
PMC: 11382444.
DOI: 10.1186/s12964-024-01811-7.
Liu J, Yuan Q, Chen X, Yang Y, Xie T, Zhang Y
Sci Rep. 2024; 14(1):17650.
PMID: 39085301
PMC: 11291735.
DOI: 10.1038/s41598-024-68385-9.
Liu J, Cai Y, He Y, Xu J, Tian S, Li Z
BMC Cancer. 2024; 24(1):123.
PMID: 38267913
PMC: 10809508.
DOI: 10.1186/s12885-024-11875-w.
Inhibition of Ephrin B2 Reverse Signaling Abolishes Multiple Myeloma Pathogenesis.
Sasine J, Kozlova N, Valicente L, Dukov J, Tran D, Himburg H
Cancer Res. 2024; 84(6):919-934.
PMID: 38231476
PMC: 10940855.
DOI: 10.1158/0008-5472.CAN-23-1950.
Effectiveness of anti-erythropoietin producing Hepatocellular receptor Type-A2 antibody in pancreatic cancer treatment.
Chang F, Tsai K, Lin T, Chiang C, Pan S, Lee Y
Heliyon. 2023; 9(11):e21774.
PMID: 38034633
PMC: 10682614.
DOI: 10.1016/j.heliyon.2023.e21774.
Combination of protein and cell internalization SELEX identifies a potential RNA therapeutic and delivery platform to treat EphA2-expressing tumors.
Santana-Viera L, Dassie J, Rosas-Lapena M, Garcia-Monclus S, Chicon-Bosch M, Perez-Capo M
Mol Ther Nucleic Acids. 2023; 32:758-772.
PMID: 37251690
PMC: 10213179.
DOI: 10.1016/j.omtn.2023.05.003.
Chronic Inhalation Exposure to Antimony Trioxide Exacerbates the MAPK Signaling in Alveolar Bronchiolar Carcinomas in B6C3F1/N Mice.
Ton T, Hong H, Kovi R, Shockley K, Peddada S, Gerrish K
Toxicol Pathol. 2023; 51(1-2):39-55.
PMID: 37009983
PMC: 11368139.
DOI: 10.1177/01926233231157322.
Combination of EphA2- and Wee1-Targeted Therapies in Endometrial Cancer.
Dasari S, Joseph R, Umamaheswaran S, Mangala L, Bayraktar E, Rodriguez-Aguayo C
Int J Mol Sci. 2023; 24(4).
PMID: 36835335
PMC: 9962847.
DOI: 10.3390/ijms24043915.
Interactions between EGFR and EphA2 promote tumorigenesis through the action of Ephexin1.
Kim J, Chang I, You H
Cell Death Dis. 2022; 13(6):528.
PMID: 35668076
PMC: 9170705.
DOI: 10.1038/s41419-022-04984-6.
ALW-II-41-27, an EphA2 inhibitor, inhibits proliferation, migration and invasion of cervical cancer cells via inhibition of the RhoA/ROCK pathway.
Li X, Li D, Ma R
Oncol Lett. 2022; 23(4):129.
PMID: 35251349
PMC: 8895465.
DOI: 10.3892/ol.2022.13249.
EPHA2, EPHA4, and EPHA7 Expression in Triple-Negative Breast Cancer.
Nikas I, Giaginis C, Petrouska K, Alexandrou P, Michail A, Sarantis P
Diagnostics (Basel). 2022; 12(2).
PMID: 35204461
PMC: 8871500.
DOI: 10.3390/diagnostics12020366.
EphrinB2-EphB4 Signaling in Neurooncological Disease.
Piffko A, Uhl C, Vajkoczy P, Czabanka M, Broggini T
Int J Mol Sci. 2022; 23(3).
PMID: 35163601
PMC: 8836162.
DOI: 10.3390/ijms23031679.
The Expression Profile and Prognostic Values of EPHA Family Members in Breast Cancer.
Zhang X
Front Oncol. 2021; 11:619949.
PMID: 34221956
PMC: 8250424.
DOI: 10.3389/fonc.2021.619949.
Insights on the Functional Role of Beta-Glucans in Fungal Immunity Using Receptor-Deficient Mouse Models.
Desamero M, Chung S, Kakuta S
Int J Mol Sci. 2021; 22(9).
PMID: 33946381
PMC: 8125483.
DOI: 10.3390/ijms22094778.
Oncogenic functions and therapeutic targeting of EphA2 in cancer.
Wilson K, Shiuan E, Brantley-Sieders D
Oncogene. 2021; 40(14):2483-2495.
PMID: 33686241
PMC: 8035212.
DOI: 10.1038/s41388-021-01714-8.
EPHA2 Interacts with DNA-PK in Cell Nucleus and Controls Ionizing Radiation Responses in Non-Small Cell Lung Cancer Cells.
Kaminskyy V, Haag P, Novak M, Vegvari A, Arapi V, Lewensohn R
Cancers (Basel). 2021; 13(5).
PMID: 33671073
PMC: 7957683.
DOI: 10.3390/cancers13051010.
EphA2 and EGFR: Friends in Life, Partners in Crime. Can EphA2 Be a Predictive Biomarker of Response to Anti-EGFR Agents?.
Cioce M, Fazio V
Cancers (Basel). 2021; 13(4).
PMID: 33572284
PMC: 7915460.
DOI: 10.3390/cancers13040700.
EphA2, vascular endothelial growth factor, and vascular endothelial growth factor correlate with adverse outcomes and poor survival in patients with glioma.
Shen L, Sun R, Kan S, Wang Z, Yu Z
Medicine (Baltimore). 2021; 100(3):e23985.
PMID: 33545987
PMC: 7837893.
DOI: 10.1097/MD.0000000000023985.